If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Baqsimi ® (glucagon) nasal powder
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is BAQSIMI™ (glucagon nasal powder) effective in children under 4 years of age?
Baqsimi (glucagon nasal powder) is not indicated for the treatment of severe hypoglycemia in pediatric patients under the age of 4 years.
Efficacy in Children
BAQSIMI is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in patients with diabetes aged 4 years and above.1
The safety and effectiveness of BAQSIMI for the treatment of severe hypoglycemia in patients with diabetes have been established in pediatric patients aged 4 years and above. Use of BAQSIMI for this indication is supported by evidence from a study in 48 pediatric patients from 4 to <17 years of age with type 1 diabetes.1
Efficacy in Children Under 4 Years of Age
The safety and effectiveness of BAQSIMI have not been established in pediatric patients younger than 4 years of age.1
Eli Lilly and Company is planning to study the use of BAQSIMI in pediatric patients from 1 to <4 years of age. More details will be available in the future.2
Enclosed Prescribing Information
1Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
2A study of nasal glucagon (LY900018) in pediatric participants with type 1 diabetes (RescuiNGkids). ClinicalTrials.gov identifier: NCT04992312. Updated September 5, 2021. Accessed September 9, 2021. https://clinicaltrials.gov/show/NCT04992312.
Date of Last Review: August 23, 2021